Copyright
©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Feb 28, 2014; 20(8): 2091-2097
Published online Feb 28, 2014. doi: 10.3748/wjg.v20.i8.2091
Published online Feb 28, 2014. doi: 10.3748/wjg.v20.i8.2091
ZD 7288, an HCN channel blocker, attenuates chronic visceral pain in irritable bowel syndrome-like rats
Yu Chen, Chun Lin, Ying Tang, Ai-Qin Chen, Cui-Ying Liu, Da-Li Lu, Laboratory for Pain Research, Key Laboratory of Brain Aging and Neurodegenerative Diseases, Center for Neuroscience Research, Department of Physiology and Pathophysiology, Fujian Medical University, Fuzhou 350108, Fujian Province, China
Author contributions: Lin C designed the research; Chen Y, Tang Y, Liu CY and Lu DL performed the experiments; Chen AQ and Lu DL analyzed the data; Chen Y and Lin C wrote the manuscript.
Supported by The Natural Science Fund of Fujian Province, No. C0910595 and No. 2012J05053; Science Fund and Doctor Initial Fund of FMU, No. 09ZD009 and No. 2010BS008
Correspondence to: Chun Lin, MD, Professor, Chief, Laboratory for Pain Research, Key Laboratory of Brain Aging and Neurodegenerative Diseases, Center for Neuroscience Research, Department of Physiology and Pathophysiology, Fujian Medical University, No. 1 Xueyuan Road, Shangjie Zhen, Minhou County, Fuzhou 350108, Fujian Province, China. chunlin77550@126.com
Telephone: +86-591-22862439 Fax: +86-591-22862439
Received: August 19, 2013
Revised: December 7, 2013
Accepted: January 8, 2014
Published online: February 28, 2014
Processing time: 190 Days and 18.6 Hours
Revised: December 7, 2013
Accepted: January 8, 2014
Published online: February 28, 2014
Processing time: 190 Days and 18.6 Hours
Core Tip
Core tip: Intrathecal administration of ZD 7288, a hyperpolarization-activated cyclic nucleotide-gated channel blocker, significantly inhibited electromyographic responses and abdominal withdrawal reflex scores and significantly increased pain thresholds in rats with chronic visceral hypersensitivity. These results are important for clinicians and the fundamental scientific community and provide scientific evidence for ZD 7288 as a novel treatment for visceral pain in irritable bowel syndrome.